Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer
{{output}}
Objectives: Non-muscle-invasive bladder cancer (NMIBC) refractory to Bacillus Calmette-Guérin (BCG) treatment recurs frequently, even with recent approved therapies. We developed a novel, solvent-free, cancer-specific nanopartic... ...
